Search - tctmd.com

Displaying 361 - 380 of 412

Sort: Relevancy | Date

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

Apixaban Recalled Following Complaints of Dose-Packaging Mismatch

Shelley Wood

June 13, 2017

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2017

Caitlin E. Cox

February 01, 2017

News Daily News

Interrupting Anticoagulation? New Guidance Aims to Simplify Periprocedural Decision-Making

Todd Neale

January 09, 2017

News Features

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

Shelley Wood

January 04, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Daily News

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

L.A. McKeown

December 13, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

Shelley Wood

November 30, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

Midlife Hypertension Linked to Late-Life Cognitive Decline

Leah Lawrence

October 11, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Todd Neale

August 27, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Advertisement

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Betrixaban Approved for Prevention of VTE

Apixaban Recalled Following Complaints of Dose-Packaging Mismatch

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

TCTMD’s Top 10 Most Popular Stories for January 2017

Interrupting Anticoagulation? New Guidance Aims to Simplify Periprocedural Decision-Making

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

TCTMD’s Top 10 Most Popular News and Features for 2016

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

TCTMD’s Top 10 Most Popular Stories for November 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Midlife Hypertension Linked to Late-Life Cognitive Decline

TCTMD’s Top 10 Most Popular Stories for August 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content